REAP Financial Group LLC Buys 317 Shares of Boston Scientific Corporation $BSX

REAP Financial Group LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 179.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 494 shares of the medical equipment provider’s stock after purchasing an additional 317 shares during the quarter. REAP Financial Group LLC’s holdings in Boston Scientific were worth $53,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. HM Payson & Co. increased its position in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after buying an additional 98 shares in the last quarter. IVC Wealth Advisors LLC increased its position in shares of Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 102 shares in the last quarter. Park Square Financial Group LLC increased its position in shares of Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after buying an additional 103 shares in the last quarter. HHM Wealth Advisors LLC increased its position in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 103 shares in the last quarter. Finally, Rise Advisors LLC boosted its stake in shares of Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 103 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $96.73 on Thursday. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The business’s fifty day simple moving average is $102.34 and its 200-day simple moving average is $101.96. The firm has a market cap of $143.33 billion, a PE ratio of 57.58, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company posted $0.62 EPS. The company’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on BSX shares. Canaccord Genuity Group lifted their price target on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. BTIG Research lifted their price target on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research note on Wednesday, October 1st. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Finally, UBS Group lifted their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus target price of $120.71.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $18,659,923.46. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.